Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.62 |
| ▸ | TYMP | P19971 | 5/20 | 0.53 |
| ▸ | PYGM | P11217 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407964 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL50827 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL24229287 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL27915600 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5219823 | 0.91 | TK2 (0.55) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5219815 | 0.91 | TK2 (0.55) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL15434595 | 0.91 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL16940274 | 0.91 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL5502489 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5502493 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2446 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485136-B2 | Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2025-12-02 | — | — | US | claimed |
| WO-2025201529-A1 | COMPOUNDS FOR SYNTHESIZING MODIFIED SMALL ACTIVATING RNA MOLECULES, MODIFIED SMALL ACTIVATING RNA MOLECULES AND USES THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-10-02 | — | — | WO | claimed |
| WO-2022089486-A1 | SIRNA FOR INHIBITING PCSK9 GENE EXPRESSION AND MODIFIER THEREOF AND USE THEREOF | 江苏柯菲平医药股份有限公司 | 2022-05-05 | — | — | WO | claimed |
| WO-2022088342-A1 | SIRNA TARGETING FOXP3 GENE AND MODIFICATION METHOD THEREFOR | 苏州吉玛基因股份有限公司 | 2022-05-05 | — | — | WO | claimed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | claimed |
| US-20130317080-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| CN-122095094-A | Compositions targeting KLKB1 and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102260-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) | EDITAS MEDICINE, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102027-A2 | COMPOSITIONS TARGETING AU-RICH ELEMENTS OF FGF21 GENE AND GDF15 GENE AND METHODS OF USE THEREOF | POSEIDA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101913-A1 | SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045437-A1 | COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997030067-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997029780-A1 | METHOXYETHOXY OLIGONUCLEOTIDES FOR MODULATION OF PROTEIN KINASE C EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |